Metabolic Disorders

Pipeline Moves: Trial completion bumps advancement prospects for AstraZeneca’s oncology drug

This week on Pipeline Moves, we look at the recent completion of a Phase I/II trial investigating AstraZeneca’s Imfinzi in…

Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise

This week on Pipeline Moves, we start with the completion of Novartis’s Phase II trial in ulcerative colitis. We also…

Innovation in biosimilars: Leading companies in hormone-based therapies for metabolic disorders

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,…

Pipeline Moves: Novartis resumes Phase II myelofibrosis trial, oncology trial completions

This week on Pipeline Moves, we look into a resumption of a Phase II trial in myelofibrosis which was previously…

Pipeline Moves: positive topline results in pulmonary hypertension, genetic and metabolic disorders

This week on Pipeline Moves, we start with positive topline results from two Phase III trials in Alagille syndrome and pulmonary…

Pipeline Moves: trial terminations in colorectal cancer, cardiovascular infections, and kidney injury

This week on Pipeline Moves, we investigate the terminations of a Phase II trial in metastatic colorectal cancer and two…

DCT Adoption Tracker reveals top therapy areas using a decentralisation approach

Telemedicine remains the leading decentralisation approach in clinical trials in Q2 of this year. The continued rise of telemedicine as…

Novo Nordisk concludes Phase II trial of CagriSema for type 2 diabetes

Novo Nordisk has concluded the Phase II clinical trial of CagriSema for treating individuals with type 2 diabetes and reported…

Top tweets: Reductions in dietary fat alter brain reward circuitry – and more

Clinical Trials Arena lists five of the top tweets on metabolic disorders in Q2 2022 based on data from GlobalData’s…

Oramed reaches 50% enrolment in Phase III trial of insulin capsule

Oramed Pharmaceuticals has enroled and randomised more than 50% of participants in its second Phase III ORA-D-013-2 international multicentre trial…